- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03284372
Safer Food Allergy Management for Adolescents
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
Among the 15 million people with food allergies in the United States, adolescents experience the highest risk of adverse events, including death from anaphylaxis. Visits to one pediatric emergency department for anaphylaxis doubled between 2001 and 2006, suggesting a rapidly escalating public health burden. Despite this critical concern, there are few evidence-based strategies to improve food allergy management in adolescents, who must sustain three core prevention strategies: diligent avoidance of allergenic foods, consistent carrying of potentially life-saving epinephrine auto-injectors, and prompt administration of epinephrine in the event of anaphylaxis.
The objective of this study is to develop and test interventions to encourage safer food allergy management among adolescents. The primary outcome is consistency of epinephrine-carrying, measured using cell phone photographs at randomly-timed check-ins. This study will be among the first to longitudinally track normative food allergy management practices and one of the first to test behavior change strategies.
In a cohort multiple randomized controlled trial (n=130), the study will include two experiments to test the effectiveness of text message reminders and incentives, using various incentive designs that have proven effective in prior behavioral economics interventions to encourage weight loss and smoking cessation. Aim 1. Test the impact of a text-message reminder system on consistency of epinephrine carrying. Aim 2. Test the impact of modest incentives on consistency of epinephrine carrying. Based on promising preliminary data, the central hypothesis is that, compared to controls, adolescents who receive text message reminders plus modest financial incentives will more consistently carry their epinephrine.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- Children's Hospital of Philadelphia
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- University of Pennsylvania
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Food allergy diagnosis by a physician and recorded in the medical chart
- Prior prescription of epinephrine auto-injector to treat anaphylaxis
- Access to a cell phone capable of sending and receiving text messages and photographs (our team will provide cell phones to participants willing to participate, but who do not own a cellphone)
- Fluent in English
- Between ages 15-19 at baseline
Exclusion Criteria:
- Unable to obtain permission (consent) of a parent to participate in the study
- Will not or cannot give assent
- Currently participating in another clinical trial with related aims
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione fattoriale
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Intervention 1
Text Message Only
|
The intervention group (n=25, randomly selected from the base cohort) will receive informational and socially supportive text messages during a 10-week intervention.
Investigators will deploy the intervention using the Way to Health platform, which automates outgoing messages and feedback.
Many of the messages will be sent to all Intervention 1 participants, to assure consistency of the intervention.
A subset will be tailored to address participants' specific allergies.
At 10 unannounced check-ins, we will send text messages asking participants in the intervention and control groups if they are carrying their epinephrine.
|
|
Sperimentale: Intervention 2, Incentive
Text message + Incentive
|
Among base cohort members not exposed to the text message only intervention (#1), we will randomly select a new intervention group (n=50) to receive text message reminders plus Incentive 1.
At each of 10 unannounced check-ins, if unsuccessful in documenting epinephrine-carrying, participants will lose part of their incentive.
The remainder of the Cohort (control) will receive text reminders.
|
|
Nessun intervento: Cohort
For the cohort multiple randomized controlled trial (cmRCT), investigators will recruit 130 participants (the base cohort) ages 15-19.
The base cohort allows investigators to measure normative food allergy self-management practices, while also serving as a control for experiments in Interventions 1 and 2.
|
|
|
Nessun intervento: Control
The baseline cohort serves as the control group in this cmRCT.
Participants will not receive text message reminders (during Intervention 1) or incentives (during Intervention 2).
However, they will participate in all data collection points, including text message check-ins to assess epinephrine-carrying. Participants in the base cohort will receive usual care.
|
|
|
Nessun intervento: Adolescent Allergy Advisors
We will pilot the text messages to be used in Interventions 1 and 2 through interviews and cognitive testing among 20 Adolescent Allergy Advisors, who will critique message content, framing, and language.
These advisors will not be part of the cohort multiple randomized controlled trial.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Proportion of check-ins at which participant is carrying epinephrine auto-injector
Lasso di tempo: 10 randomly timed check-ins during the 10-week intervention period
|
Proportion of check-ins at which participant is carrying epinephrine auto-injector, measured using cell phone photographs
|
10 randomly timed check-ins during the 10-week intervention period
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Characterize adolescents' normative food allergy management practices
Lasso di tempo: Year-long cohort study
|
Characterize adolescents' normative food allergy management practices, measured comparing baseline and follow-up surveys that assess social challenges, out-of-home eating, allergen avoidance, and response to adverse events.
|
Year-long cohort study
|
|
Characterize adolescents' normative food allergy management practices
Lasso di tempo: Year-long cohort study
|
Characterize adolescents' normative food allergy management practices, measured using periodic text-message questions that assess social challenges, out-of-home eating, allergen avoidance, and response to adverse events.
|
Year-long cohort study
|
|
Develop a set of text message reminders to promote safer food allergy management among adolescents
Lasso di tempo: 2-year project period
|
Develop a set of text message reminders to promote safer food allergy management among adolescents by cognitively testing text message content
|
2-year project period
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Carolyn C Cannuscio, ScD, University of Pennsylvania
- Investigatore principale: Jonathan Spergel, MD, Children's Hospital of Philadelphia
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 827073
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Text Message Only
-
Boston UniversityNational Cancer Institute (NCI); Brown University; National Institutes of Health... e altri collaboratoriCompletato
-
Fundació d'investigació Sanitària de les Illes...CompletatoDiabete mellito, tipo 2Spagna
-
The University of Hong KongNon ancora reclutamentoIntervento | ControlloHong Kong
-
Ottawa Heart Institute Research CorporationCanadian Institutes of Health Research (CIHR); AbbottReclutamentoFibrillazione atriale | Ablazione transcatetere con radiofrequenza | Ablazione transcatetereCanada
-
Fundació d'investigació Sanitària de les Illes...CompletatoStato prediabeticoSpagna
-
Washington University School of MedicineNovartis; National Comprehensive Cancer NetworkNon ancora reclutamentoCancro al seno | Cancro al senoStati Uniti
-
Taipei Medical UniversityCompletato
-
Fundació d'investigació Sanitària de les Illes...CompletatoDiabete mellito, tipo 2Spagna
-
Scripps Whittier Diabetes InstituteReclutamentoDiabete di tipo 2Stati Uniti
-
Yale UniversityCompletatoCancro al seno | Aderenza, Farmaco | Effetto collateraleStati Uniti